Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 72Carcinoma, Renal Cell 26Kidney Neoplasms 22Skin Neoplasms 16Neoplasm Metastasis 14Leukemia, Myeloid, Acute 13Leukemia 13Breast Neoplasms 11Lymphoma 10Lymphoma, Non-Hodgkin 9Ovarian Neoplasms 8Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Pancreatic Neoplasms 5Neuroblastoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Congenital Abnormalities 5Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Hodgkin Disease 4Gliosarcoma 4Glioblastoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

Tacrolimus 38Cyclophosphamide 27Methotrexate 26Mycophenolic Acid 21Cyclosporine 21Busulfan 21fludarabine phosphate 20Antilymphocyte Serum 20Melphalan 15fludarabine 13Sirolimus 13Methylprednisolone 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 10thymoglobulin 9Stem Cell Transplantation 8Radiotherapy 7ruxolitinib 6Thiotepa 6Rituximab 6Granulocyte Colony-Stimulating Factor 6Prednisone 5Hematopoietic Stem Cell Transplantation 5Filgrastim 5Alemtuzumab 5Transplantation 4Etoposide 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Pentostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Graft vs Host Disease × aldesleukin × Clear all
NCT01390402 2016-02-03

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 3 charts
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡